Cytokinetics Clinical Trials: 41 Led Studies

Archive historyApr 2023 to Dec 2025

41 recorded changes across Cytokinetics trials

Every status move, completion date shift and enrollment change ComplyRx has recorded across 11 of these trials. One is shown below.

Enrollment changeEnrollment grew to 55 from 40NCT06412666 · recorded 1 Dec 2025

Track to read them

+37 more recorded changes · Track a drug to see every change the night it lands

Track aficamten

Most active programmes

The drugs appearing most often across Cytokinetics's recently active trials. Comparator arms are excluded.

CK-182745218 trials
omecamtiv mecarbil10 trials
Omecamtiv mecarbil4 trials
Aficamten3 trials
Reldesemtiv3 trials
500 mg CK-20173573 trials

Upcoming readouts

Next primary completion dates among Cytokinetics's active phase 2 and phase 3 trials. Dates are registry estimates and move often, which is exactly what the tracker watches.

Sept 2026AMBER-HFpEF: AMBER-HFpEF: Assessment of CK-4021586 in a Multi-Center, Blinded Evaluation of Safety and Tolera…Phase 2
Sept 2027COMET-HF: Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced …Phase 3
Jan 2030CEDAR-HCM: A Study to Evaluate the Effect of Aficamten in Pediatric Patients With Symptomatic Obstructive H…Phase 2

Top therapeutic areas

Conditions studied most often across Cytokinetics's recently active trials.

Heart Failure10 trials
Amyotrophic Lateral Sclerosis8 trials
Heart Failure With Reduced Ejection Fraction3 trials
Obstructive Hypertrophic Cardiomyopathy (oHCM)2 trials
Symptomatic Obstructive Hypertrophic Cardiomyopathy2 trials
Symptomatic Heart Failure With Preserved Ejection Fraction (HFpEF)1 trial

Cytokinetics trials

The 41 most significant of Cytokinetics's recently active trials, soonest estimated readout first.
Select any row for the full record; the change timeline unlocks with tracking.

Trial	Phase	Stability	Status	Enrollment	Est. readout
AMBER-HFpEFAMBER-HFpEF: Assessment of CK-4021586 in a Multi-Center, Blinded Evaluation of Safety and Tolerability Results in HFpEFNCT06793371CK-4021586 (150 mg, 300 mg, 450 mg, and 600 mg)	Phase 2	Locked · track to reveal	OngoingRecruiting	60 est.	Sept 2026
Omecamtiv Mecarbil Post-trial Access StudyNCT04464525Omecamtiv mecarbil	Phase 3	Locked · track to reveal	StoppedWithdrawn	0 est.	27 Nov 2026
COMET-HFStudy With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection FractionNCT06736574Omecamtiv Mecarbil (OM)	Phase 3	Locked · track to reveal	OngoingRecruiting	1,800 est.	Sept 2027
FOREST-HCMOpen-label Extension Study to Evaluate the Long-term Safety and Tolerability of Aficamten in Adults With HCMNCT04848506Aficamten (5 - 20 mg)	Phase 2	Locked · track to reveal	OngoingEnrolling by invitation	900 est.	Mar 2028
CEDAR-HCMA Study to Evaluate the Effect of Aficamten in Pediatric Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM).NCT06412666Aficamten	Phase 2	Locked · track to reveal	OngoingRecruiting	55 est.	Jan 2030
ACACIA-HCMPhase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic nHCMNCT06081894Aficamten	Phase 3	Locked · track to reveal	OngoingActive, not recruiting	500 est.	Jun 2026
MAPLE-HCMPhase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Metoprolol Succinate in Adults With Symptomatic oHCMNCT05767346Aficamten (CK-3773274) (5 mg, 10 mg, 15 mg and 20 mg)	Phase 3	Locked · track to reveal	Completed	175 est.	28 Feb 2025
A Single and Multiple Ascending Dose Study of CK-4021586 in Healthy Adult ParticipantsNCT05877053CK-4021586	Phase 1	Locked · track to reveal	Completed	102 est.	20 Nov 2024
Study to Evaluate the Effect of Aficamten Administration on QT/QTc IntervalNCT05924815Aficamten	Phase 1	Locked · track to reveal	Completed	44 est.	14 Nov 2023
SEQUOIA-HCMPhase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic oHCMNCT05186818Aficamten (5 mg, 10 mg, 15 mg, and 20 mg)	Phase 3	Locked · track to reveal	Completed	282 est.	10 Nov 2023
A Single and Multiple Ascending Dose Study of CK-3828136 in Healthy Adult ParticipantsNCT05662215CK-3828136	Phase 1	Locked · track to reveal	StoppedTerminated	57 est.	8 Aug 2023
COURAGE-ALSA Study to Evaluate the Efficacy and Safety of Reldesemtiv in Patients With Amyotrophic Lateral Sclerosis (ALS)NCT04944784Reldesemtiv	Phase 3	Locked · track to reveal	StoppedTerminated	489 est.	18 Jul 2023
A Phase 3, Open-Label Extension of COURAGE-ALS (CY 5031)NCT05442775Reldesemtiv	Phase 3	Locked · track to reveal	StoppedTerminated	71 est.	7 Jun 2023
REDWOOD-HCMDose-finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CK-3773274 in Adults With Hypertrophic CardiomyopathyNCT04219826CK-3773274 (5 - 15 mg)	Phase 2	Locked · track to reveal	Completed	96 est.	28 Feb 2023
METEORIC-HFStudy to Assess the Effect of Omecamtiv Mecarbil on Exercise Capacity in Subjects With Heart FailureNCT03759392Omecamtiv Mecarbil	Phase 3	Locked · track to reveal	Completed	276 est.	8 Nov 2021
GALACTIC-HFRegistrational Study With Omecamtiv Mecarbil (AMG 423) to Treat Chronic Heart Failure With Reduced Ejection FractionNCT02929329Omecamtiv Mecarbil	Phase 3	Locked · track to reveal	Completed	8,256 est.	14 Sept 2020
Study to Assess the Effect of Omecamtiv Mecarbil (OM) on QT/QTc Intervals in Healthy AdultsNCT04175808Omecamtiv Mecarbil (OM)	Phase 1	Locked · track to reveal	Completed	70 est.	4 Mar 2020
A Single and Multiple Ascending Dose Study of CK-3773274 in Healthy Adult SubjectsNCT03767855CK-3773274 - Granules in Capsule	Phase 1	Locked · track to reveal	Completed	114 est.	3 Jan 2020
FORTITUDE-ALSA Study to Evaluate Efficacy, Safety and Tolerability of CK-2127107 in Patients With Amyotrophic Lateral Sclerosis (ALS)NCT03160898Reldesemtiv	Phase 2	Locked · track to reveal	Completed	458 est.	7 Mar 2019
VIGOR-ALSA Study for Patients Who Completed VITALITY-ALS (CY 4031)NCT02936635tirasemtiv	Phase 3	Locked · track to reveal	Completed	280 est.	26 Oct 2018
A Study of CK-2127107 in Patients With Spinal Muscular AtrophyNCT02644668Reldesemtiv 150 mg	Phase 2	Locked · track to reveal	Completed	70 est.	31 May 2018
Safety, PK, and Efficacy of Omecamtiv Mecarbil in Japanese Subjects With Heart Failure With Reduced Ejection FractionNCT0269542025 mg Omecamtiv Mecarbil	Phase 2	Locked · track to reveal	Completed	81 est.	6 Apr 2017
VITALITY-ALSVentilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices After Treatment for a YearNCT02496767Tirasemtiv	Phase 3	Locked · track to reveal	Completed	744 est.	9 Mar 2017
Pharmacokinetics and Safety Study of Omecamtiv Mecarbil in Healthy Japanese AdultsNCT02601001Omecamtiv mecarbil	Phase 1	Locked · track to reveal	Completed	50 est.	6 Jan 2016
COSMIC-HFCOSMIC-HF - Chronic Oral Study of Myosin Activation to Increase Contractility in Heart FailureNCT01786512Omecamtiv Mecarbil Matrix F1 Formulation	Phase 2	Locked · track to reveal	Completed	544 est.	22 Jul 2015
Study of Safety, Tolerability & Efficacy of CK-2017357 in Amyotrophic Lateral Sclerosis (ALS)NCT01709149CK-2017357	Phase 2	Locked · track to reveal	Completed	711 est.	Mar 2014
Study to Evaluate the Safety and Efficacy of IV Infusion Treatment With Omecamtiv Mecarbil in Subjects With Left Ventricular Systolic Dysfunction Hospitalized for Acute Heart Failure (ATOMIC-AHF)NCT01300013Omecamtiv mecarbil	Phase 2	Locked · track to reveal	Completed	614 est.	Apr 2013
Pharmacokinetics Study of AMG 423 in Healthy Subjects and Subjects With Various Degrees of Renal InsufficiencyNCT01737866AMG 423	Phase 1	Locked · track to reveal	Completed	13 est.	Jan 2013
Pharmacodynamic Study of CK-2017357 in Patients With Generalized Myasthenia GravisNCT01268280250 mg CK-2017357	Phase 2	Locked · track to reveal	StoppedTerminated	32 est.	Oct 2012
A Study to Evaluate the Effects of Multiple Doses of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)NCT01378676CK-2017357 (Part A)	Phase 2	Locked · track to reveal	Completed	49 est.	Mar 2012
Dose Titration Study to Test Safety and Effects of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)NCT01486849CK-2017357	Phase 2	Locked · track to reveal	Completed	27 est.	Mar 2012
Pharmacokinetic Study of Omecamtiv Mecarbil in Heart Failure PatientsNCT01077167Omecamtiv mecarbil	Phase 2	Locked · track to reveal	StoppedWithdrawn	0 est.	May 2011
A Study of CK-2017357 in Patients With Peripheral Artery Disease and Symptomatic ClaudicationNCT01131013375 mg CK-2017357	Phase 2	Locked · track to reveal	Completed	61 est.	Mar 2011
A Study of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)NCT01089010250 mg CK-2017357	Phase 2	Locked · track to reveal	Completed	67 est.	Nov 2010
A Study of SB-743921 in Non-Hodgkin Lymphoma and Hodgkin LymphomaNCT00343564SB-743921	Phase 1	Locked · track to reveal	Completed	68 est.	Jul 2010
A Study of Ispinesib in Metastatic Breast CancerNCT00607841Ispinesib	Phase 1	Locked · track to reveal	StoppedTerminated	16 est.	Nov 2009
Pharmacokinetics of Oral CK-1827452 in Patients With Stable Heart FailureNCT00941681CK-1827452	Phase 2	Locked · track to reveal	Completed	35 est.	Oct 2009
A Study of CK-1827452 Infusion in Stable Heart FailureNCT00624442CK-1827452	Phase 2	Locked · track to reveal	Completed	45 est.	Feb 2009
PK and Tolerability of IV and Oral CK-1827452 in Patients With Ischemic Cardiomyopathy and AnginaNCT00682565CK-1827452 24mg and 6 mg iv infusion	Phase 2	Locked · track to reveal	Completed	94 est.	Nov 2008
Phase II Study of the Effect of CK-1827452 Injection on Myocardial EfficiencyNCT00748579CK-1827452	Phase 2	Locked · track to reveal	StoppedTerminated	2 est.	Nov 2008
A Pharmacokinetic and Pharmacodynamic Study of Omecamtiv Mecarbil in Healthy VolunteersNCT01380223omecamtiv mecarbil	Phase 1	Locked · track to reveal	Completed	35 est.	Apr 2006

View all trials41

MAPLE-HCM: Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Metoprolol Succinate in Adults With Symptomatic oHCM

Phase 3CompletedNCT05767346 ↗

Primary completion: Feb 2025; actual
Enrollment: 175; estimated
Start: Jun 2023; Cytokinetics

Conditions

Obstructive Hypertrophic Cardiomyopathy (oHCM)

Interventions

Aficamten (CK-3773274) (5 mg, 10 mg, 15 mg and 20 mg)
Placebo to match aficamten
Metoprolol succinate (50 mg, 100 mg, 150 mg and 200 mg)
Placebo to match metoprolol succinate

Brief summary

The purpose of this study is to compare the efficacy and safety of aficamten (CK-3773274) compared with metoprolol succinate in adults with symptomatic hypertrophic cardiomyopathy and left ventricular outflow tract obstruction

Full record on ClinicalTrials.gov ↗

Change timeline

5 recorded · latest 1 Jul 2025

Status change · 3

Completion date move · 1

Enrollment change · 1

Track Cytokinetics drugs to see every change the night it lands.

Track aficamten

A Single and Multiple Ascending Dose Study of CK-4021586 in Healthy Adult Participants

Phase 1CompletedNCT05877053 ↗

Primary completion: Nov 2024; actual
Enrollment: 102; estimated
Start: May 2023; Cytokinetics

Conditions

Healthy Participants

Interventions

CK-4021586
Placebo for CK-4021586

Brief summary

The purposes of this study are to: * Learn about the safety and tolerability of CK 4021586 after a single dose and multiple doses in healthy subjects. * Find out how much CK-4021586 is in the blood after a single dose and multiple doses. * Determine the effect different doses of CK-4021586 on the pumping function of…

Full record on ClinicalTrials.gov ↗

Change timeline

4 recorded · latest 1 Jul 2025

Completion date move · 2

Status change · 1

Enrollment change · 1

Track Cytokinetics drugs to see every change the night it lands.

Track aficamten

Study to Evaluate the Effect of Aficamten Administration on QT/QTc Interval

Phase 1CompletedNCT05924815 ↗

Primary completion: Nov 2023; actual
Enrollment: 44; estimated
Start: May 2023; Cytokinetics

Conditions

Healthy Participants

Interventions

Aficamten
Aficamten-matching Placebo
Moxifloxacin

Brief summary

This is a single-center, 2-part (Part A and Part B) study in healthy participants. Part A (Dose Finding) is an open-label, SAD study to identify the dose for Part B. Part B (TQT Study) is a randomized, double-blind (with respect to aficamten and matching placebo), positive- and placebo-controlled, single-dose, 3-way…

Full record on ClinicalTrials.gov ↗

Change timeline

5 recorded · latest 1 Jan 2024

Enrollment change · 2

Status change · 2

Completion date move · 1

Track Cytokinetics drugs to see every change the night it lands.

Track aficamten

SEQUOIA-HCM: Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic oHCM

Phase 3CompletedNCT05186818 ↗

Primary completion: Nov 2023; actual
Enrollment: 282; estimated
Start: Feb 2022; Cytokinetics

Conditions

Obstructive Hypertrophic Cardiomyopathy (oHCM)

Interventions

Aficamten (5 mg, 10 mg, 15 mg, and 20 mg)
Placebo to match aficamten

Brief summary

The purpose of this study is to evaluate the efficacy and safety of aficamten (CK-3773274) versus placebo in adults with symptomatic hypertrophic cardiomyopathy (HCM) and left ventricular outflow tract obstruction.

Full record on ClinicalTrials.gov ↗

Change timeline

4 recorded · latest 1 Apr 2024

Status change · 2

Completion date move · 1

Enrollment change · 1

Track Cytokinetics drugs to see every change the night it lands.

Track aficamten

A Single and Multiple Ascending Dose Study of CK-3828136 in Healthy Adult Participants

Phase 1TerminatedNCT05662215 ↗

Primary completion: Aug 2023; actual
Enrollment: 57; estimated
Start: Dec 2022; Cytokinetics

Conditions

Healthy Participants

Interventions

CK-3828136
Placebo for CK-3828136

Brief summary

1. Learn about the safety and tolerability of CK-3828136 after a single dose and multiple doses in healthy subjects. 2. Find out how much CK-3828136 is in the blood after a single dose and multiple doses. 3. Determine the effect different doses of CK-3828136 on the pumping function of the heart.

Full record on ClinicalTrials.gov ↗

Change timeline

4 recorded · latest 1 Jan 2025

Completion date move · 2

Status change · 1

Enrollment change · 1

Track Cytokinetics drugs to see every change the night it lands.

Track aficamten

A Single and Multiple Ascending Dose Study of CK-3773274 in Healthy Adult Subjects

Phase 1CompletedNCT03767855 ↗

Primary completion: Jan 2020; actual
Enrollment: 114; estimated
Start: Dec 2018; Cytokinetics

Conditions

Symptomatic Obstructive Hypertrophic Cardiomyopathy
Healthy Subjects

Interventions

CK-3773274 - Granules in Capsule
Placebo - Granules in Capsule
CK-3773274 - Tablets

Brief summary

The purposes of this study are to: 1. Learn about the safety of CK-3773274 after a single dose and multiple doses in healthy subjects. 2. Learn how healthy subjects tolerate CK-3773274 after a single dose and multiple doses. 3. Find out how much CK-3773274 is in the blood after a single dose and multiple doses. 4.…

Full record on ClinicalTrials.gov ↗

Change timeline

No changes recorded on this trial in the observed window.

COSMIC-HF: COSMIC-HF - Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure

Phase 2CompletedNCT01786512 ↗

Primary completion: Jul 2015; actual
Enrollment: 544; estimated
Start: Feb 2013; Cytokinetics

Conditions

Modified Release Oral Formulation
Left Ventricular Systolic Dysfunction
Chronic Heart Failure
History of Chronic Heart Failure
Left Ventricular Ejection Fraction
Pharmacokinetics
Echocardiogram

Interventions

Omecamtiv Mecarbil Matrix F1 Formulation
Omecamtiv Mecarbil Matrix F2 Formulation
Placebo
Omecamtiv Mecarbil Swellable Core Technology F2

Brief summary

The primary objectives of this study are (i) to select an oral modified release (MR) formulation and dose of omecamtiv mecarbil for chronic twice daily (BID) dosing in adults with heart failure and left ventricular systolic dysfunction and (ii) to characterize its pharmacokinetics (PK) over 20 weeks of treatment.

Full record on ClinicalTrials.gov ↗

Change timeline

No changes recorded on this trial in the observed window.

Study to Evaluate the Safety and Efficacy of IV Infusion Treatment With Omecamtiv Mecarbil in Subjects With Left Ventricular Systolic Dysfunction Hospitalized for Acute Heart Failure (ATOMIC-AHF)

Phase 2CompletedNCT01300013 ↗

Primary completion: Apr 2013; actual
Enrollment: 614; estimated
Start: Apr 2011; Cytokinetics

Conditions

Heart Failure

Interventions

Placebo
Omecamtiv mecarbil

Brief summary

The primary objective of the study is to evaluate the effect of 48 hours of intravenous (IV) omecamtiv mecarbil compared with placebo on dyspnea in subjects with left ventricular systolic dysfunction hospitalized for acute heart failure. This is a multicenter, randomized, double-blind, placebo-controlled study with 3…

Full record on ClinicalTrials.gov ↗

Change timeline

No changes recorded on this trial in the observed window.

A Study to Evaluate the Effects of Multiple Doses of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)

Phase 2CompletedNCT01378676 ↗

Primary completion: Mar 2012; actual
Enrollment: 49; estimated
Start: Jun 2011; Cytokinetics

Conditions

Amyotrophic Lateral Sclerosis

Interventions

Placebo (Part A)
CK-2017357 (Part A)
CK-2017357 (Part A)
CK-2017357 (Part A)
Riluzole 50 MG (Part B)
Placebo (Part B)
CK-2017357 (Part B)
CK-2017357 (Part B)

Brief summary

The study will generate data on safety, tolerability and pharmacokinetics after multiple daily doses of CK-2017357 in patients with ALS. Patients will be randomized into one of four different treatment groups, receiving daily oral doses of either placebo, 125 mg, 250 mg, or 375 mg of CK-2017357 for 14 days.

Full record on ClinicalTrials.gov ↗

Change timeline

No changes recorded on this trial in the observed window.